Big Data in the Pharmaceutical Sector between Protection and Transparency: Opportunities and Legal Challenges

AddThis Social Bookmark Button

27 February 2019 | Basel

If you would like to receive more information about this event, please contact Jakob McKernan.



Overview


Data in the healthcare and pharmaceutical sector play an important role in various aspects. Data has already transformed many facets of the sector. Huge datasets are driving new drug discoveries and are making clinical trials more efficient. Wearable devises such sleep trackers are creating more informed patients and the employment of more sophisticated data models has enabled healthcare professionals better to predict and prevent illness. From personalised medicine to AI assisted diagnostics and genetic engineering and sequencing, the possibilities, it seems, are endless.

However, despite its potential to improve patient care and the share price of pharmaceutical companies, legal and regulatory challenges remain. One need to look no further than the recent introduction of the General Data Protection Regulation (GDPR) to realise that significant regulatory challenges exists. With patients and regulatory becoming increasingly cognizant of data protection issues, regulatory restrictions are only going to increase.  

Methodology


This one-day conference is specifically designed to help you navigate these challenges and recognise opportunities. Aimed at practitioners, regulators and academics alike, this event will help to avoid legal pitfalls and embrace opportunities as the healthcare sector enters into the era of big data.

During the conference the following topics will be discussed:

  • Big data in the pharmaceutical sector - Current developments and legal challenges
  • Data protection issues resulting from personalized medicine and pay for performance (P4P)
  • Regulator’s standpoint
  • Using data to reduce the number of clinical trials: Regulatory issues
  • The case for ‘open source’ pharma
  • How eliminating data silos will democratize pharma R&D
  • Blockchain and datasharing in the pharma sector

Who should participate?

  • Inhouse Legal Counsel
  • Compliance and Data Protection Officer
  • Regulatory Affairs Officer
  • Life Science Attorneys
  • Regulators
  • Academics
  • Researchers

 
 

EPLR
European Pharmaceutical Law Review
Publication frequency: quarterly
approx. 60 pages
ISSN 25 11-71 57

Further information

In cooperation with:

Pharma



EStAL
Journal
Publication frequency: quarterly
Subscription: € 442,-
ISSN 16 19-52 72

Further information
This website uses Google Analytics for internal evaluation purposes. To prevent Google’s collection and use of data: click this link. An opt-out-cookie will be implemented. Please find more information in our data privacy information